At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
Tandem Microsphere loaded with Epirubicindevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Trial of Transcatheter Arterial Chemoembolization With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
In Brief
A clinical study evaluating Tandem Microsphere loaded with Epirubicin for Localized Hepatocellular Carcinoma. Completed, enrolled 109 participants across 10 sites.
Detailed Summary
A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocalized Hepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartOct 2017
Primary CompletionJun 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 14, 2017
Enrollment StartOct 24, 2017
Primary CompletionJun 28, 2019
Study CompletionFeb 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.2 years ago
Interventions
Tandem Microsphere loaded with Epirubicindevice
The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)